Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 325

Sort by

Sort Order Select

Journal Articles

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Andreas Tiede, Ulrich J. Sachs, Andreas Czwalinna, Sonja Werwitzke, Rolf Bikker, Joachim K. Krauss, Frank Donnerstag, Karin Weißenborn, Günter Höglinger, Benjamin Maasoumy, Heiner Wedemeyer, Arnold Ganser

Blood (2021) 138 (4): 350–353.

https://doi.org/10.1182/blood.2021011958

Published: 2021

Includes: Supplemental data

Journal Articles

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Blood (2021) 137 (18): 2438–2449.

https://doi.org/10.1182/blood.2020009280

Published: 2021

Includes: Supplemental data

Journal Articles

Eculizumab and aHUS: to stop or not

Robert A. Brodsky

Blood (2021) 137 (18): 2419–2420.

https://doi.org/10.1182/blood.2020010234

Published: 2021

Journal Articles

How I treat paroxysmal nocturnal hemoglobinuria

Robert A. Brodsky

Blood (2021) 137 (10): 1304–1309.

https://doi.org/10.1182/blood.2019003812

Published: 2021

Journal Articles

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

Sonata Jodele, Christopher E. Dandoy, Adam Lane, Benjamin L. Laskin, Ashley Teusink-Cross, Kasiani C. Myers, Gregory Wallace, Adam Nelson, Jack Bleesing, Ranjit S. Chima, Russel Hirsch, Thomas D. Ryan, Stefanie Benoit, Kana Mizuno, Mikako Warren, Stella M. Davies

Blood (2020) 135 (13): 1049–1057.

https://doi.org/10.1182/blood.2019004218

Published: 2020

Includes: Supplemental data

Journal Articles

A complementary new drug for PNH

Robert A. Brodsky

Blood (2020) 135 (12): 884–885.

https://doi.org/10.1182/blood.2020004959

Published: 2020

Journal Articles

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Blood (2020) 135 (12): 912–920.

https://doi.org/10.1182/blood.2019003399

Published: 2020

Includes: Supplemental data

Journal Articles

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Pallavi Kopparthy, MD, Anita Rajasekhar, MD

Blood (2019) 134 (Supplement_1): 4899.

https://doi.org/10.1182/blood-2019-131846

Published: 2019

Journal Articles

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Wynne Weston-Davies, Tadeusz Robak, MD, Miles Nunn, PhD, Agnieszka Piekarska, MD, Anna Szmigielska-Kaplon, MD, Anita Hill, MD PhD

Blood (2019) 134 (Supplement_1): 4797.

https://doi.org/10.1182/blood-2019-125263

Published: 2019

Journal Articles

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Jessica J Jalbert, PhD, Umesh Chaudhari, MD, Haixin Zhang, MSc, Jonathan Weyne, MD, Jamile M. Shammo, MD

Blood (2019) 134 (Supplement_1): 3407.

https://doi.org/10.1182/blood-2019-125867

Published: 2019

Journal Articles

Utility of Thrombophilia Testing in Portal Vein Thrombosis in a Large Single Institutional Cohort

Douglas Tremblay, MD, Leonard Naymagon, MD, Kevin Troy, MD, Caroline Cromwell, MD, Colleen Edwards, MD, Thomas Schiano, MD, Marina Kremyanskaya, John Mascarenhas, MD

Blood (2019) 134 (Supplement_1): 3646.

https://doi.org/10.1182/blood-2019-123651

Published: 2019

Journal Articles

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Austin Kulasekararaj, MBBS MDMRCP FRCPath, Antonio M. Risitano, MD PhD, Jaroslaw P. Maciejewski, MD PhD, Rosario Notaro, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Jong-Wook Lee, MD, Mingjun Huang, PhD, Michael Geffner, MD, Robert A. Brodsky, MD

Blood (2019) 134 (Supplement_1): 3514.

https://doi.org/10.1182/blood-2019-124748

Published: 2019

Journal Articles

Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade

Aakash Putta, MD MBBS, Hafeez Shaka, MD, Shristi Upadhyay Banskota, MD, Sunny R K Singh, MD, Sindhu Malapati, MD, Muhammad Zain Farooq, MD MBBS, Kumar Kunnal Batra, MD

Blood (2019) 134 (Supplement_1): 3691.

https://doi.org/10.1182/blood-2019-124265

Published: 2019

Journal Articles

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

Pierre-Edouard Debureaux, MD, Fabiana Cacace, Bruno G.P. Silva, MD, Federica Barone, MD, Rodrigo T Calado, MD, Flore Sicre de Fontbrune, Juliette Soret-Dulphy, MD, Patrizia Ricci, Michela Sica, PhD, Rosario Notaro, MD, Phillip Scheinberg, MD, Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Antonio M. Risitano, MD PhD, Régis Peffault de Latour, MD PhD, Camilla Frieri, MD

Blood (2019) 134 (Supplement_1): 3517.

https://doi.org/10.1182/blood-2019-125917

Published: 2019

Journal Articles

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Lauren M Panebianco, MD, Teresa Gentile, MD PhD

Blood (2019) 134 (Supplement_1): 4872.

https://doi.org/10.1182/blood-2019-128297

Published: 2019

Journal Articles

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Vladimir Hanes, MD, Jean Pan, Daniel T. Mytych, PhD, David Chien, MD, Vincent Chow

Blood (2019) 134 (Supplement_1): 3520.

https://doi.org/10.1182/blood-2019-128621

Published: 2019

Journal Articles

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Iara Baldim Rabelo Gomes, MD PhD, Vinicius Campos de Molla, MD, Andre Domingues Pereira, MD, Roberta Shcolnik Szor, MD, Martha Mariana Arruda, MD PhD, Maria Stella Figueiredo, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2222.

https://doi.org/10.1182/blood-2019-132023

Published: 2019

Journal Articles

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Ka-Won Kang, Hyemi Moon, Byung-Hyun Lee, MD, Min Ji Jeon, Eun Sang Yu, MD, Dae Sik Kim, Se Ryeon Lee, Hwa Jung Sung, Seok Jin Kim, MD PhD, Chul Won Choi, Byung Soo Kim, Juneyoung Lee, Yong Park

Blood (2019) 134 (Supplement_1): 2227.

https://doi.org/10.1182/blood-2019-125269

Published: 2019

Journal Articles

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

Patricia Eiko Yamakawa, MD, Ana Rita Da Fonseca, MD, Matheus Vescovi, MD PhD, Iara Baldim Rabelo Gomes, MD PhD, Ismael Dale Cotrim Guerreiro da Silva, MD PhD, Celso Arrais-Rodrigues, MD PhD

Blood (2019) 134 (Supplement_1): 2229.

https://doi.org/10.1182/blood-2019-126241

Published: 2019

Journal Articles

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Austin Kulasekararaj, MDMBBS,MRCP,FRCPath, Anita Hill, MD PhD, Saskia Langemeijer, MD PhD, Richard A. Wells, MD DPhil, F. Ataulfo Gonzalez-Fernandez, Anna Gaya, Emilio Ojeda Gutierrez, Caroline I. Piatek, Lindsay D Mitchell, MBChB, MRCP(UK), FRCPath, Kensuke Usuki, Alberto Bosi, Robert A. Brodsky, MD, Masayo Ogawa, MD FAAP, Ji Yu, Stephan Ortiz, RPh, PhD, Alexander Röth, MD PhD, Jong-Wook Lee, MD PhD, Régis Peffault de Latour, MD PhD

Blood (2019) 134 (Supplement_1): 2231.

https://doi.org/10.1182/blood-2019-128746

Published: 2019

NARROW

Prothrombotic immune thrombocytopenia after COVID-19 vaccination

Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study

Eculizumab and aHUS: to stop or not

How I treat paroxysmal nocturnal hemoglobinuria

Complement blockade for TA-TMA: lessons learned from a large pediatric cohort treated with eculizumab

A complementary new drug for PNH

The complement C5 inhibitor crovalimab in paroxysmal nocturnal hemoglobinuria

Thrombotic Thrombocytopenic Purpura and Atypical Hemolytic Uremic Syndrome in Pregnancy: A Single Center Retrospective Review

Long Term Nomacopan Administration Results in Complete Transfusion Independence in Previously Transfusion-Dependent PNH Patients

Epidemiology of PNH and Real-World Treatment Patterns Following an Incident PNH Diagnosis in the US

Utility of Thrombophilia Testing in Portal Vein Thrombosis in a Large Single Institutional Cohort

A Phase 2 Open-Label Study of Danicopan (ACH-0144471) in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Who Have an Inadequate Response to Eculizumab Monotherapy

Therapeutic Plasma Exchange (PLEX) in Thrombotic Microangiopathy (TMA): Experiences of an Inner-City Hospital over a Decade

Hematological Response to Eculizumab in Paroxysmal Nocturnal Hemoglobinuria: Application of a Novel Classification to Identify Unmet Clinical Needs and Future Clinical Goals

The Role of Monitoring Complement Levels in Catastrophic Antiphospholipid Syndrome: A Case Series of 4 Patients

Relationship between Pharmacokinetics and Antidrug Antibody Status of ABP 959, a Biosimilar Candidate to Eculizumab: Results from a Pharmacokinetic Similarity Study

Clinical Characteristics of Brazilian Patients with Paroxysmal Nocturnal Hemoglobinuria and Changing Prognosis with Eculizumab

Real-World Efficacy of Eculizumab for Paroxysmal Nocturnal Hemoglobinuria in South Korea: Paradox of Eculizumab

Metabolomic Profile in Patients with Paroxysmal Nocturnal Hemoglobinuria

One-Year Efficacy and Safety from a Phase 3 Trial of Ravulizumab in Adult Patients with Paroxysmal Nocturnal Hemoglobinuria Receiving Prior Eculizumab Treatment

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only